Clinical trials: Thyroid Hormones
Differentiated Thyroid Cancer
A New Study to Follow-up Thyroid Cancer Patients Who Participated in a Previous Study, Which Compared the Success of Destruction of the Thyroid Remnant Using Standard Treatment or Thyrogen.
Patients diagnosed with thyroid cancer are commonly treated with surgery to remove their thyroid gland followed by radioiodine ablation to destroy any remaining parts of the thyroid gland that may have been missed during surgery.
- Trial name
- NCT00295763
- Testing
- Thyrogen (thyrotropin alfa for injection)
- Where
- 9 sites in United States, Canada and 3 more
- Volunteers
- 61 people
- Sponsor
- Genzyme, a Sanofi Company
Solid Tumor, TNBC - Triple-Negative Breast Cancer
TH1902 in Patients With Advanced Solid Tumors
Open label first-in-human study of TH1902 in solid cancer, with 4 sequential parts: Part 1 (dose escalation): patients with recurrent advanced solid tumors (all comers) that have relapsed or are refractory to standard…
- Conditions
- Solid Tumor, TNBC - Triple-Negative Breast Cancer, Hormone Receptor-positive Breast Cancer, Epithelial Ovarian Cancer
- Trial name
- NCT04706962
- Testing
- TH1902
- Where
- 6 sites in United States, Canada
- Volunteers
- 70 people
- Sponsor
- Theratechnologies
Hypothyroidism
Study to Verify Clinical Utility of Point-of-Care (POC) Thyroid Stimulating Hormone (TSH) Test Kits as Compared to Third Generation TSH Test Kit
This is a Phase 4, single-center, open-label, interventional study, wherein all enrolled subjects will be tested for Thyroid Stimulating Hormone (TSH) by using the quantitative and the qualitative Point-of-Care (POC) TSH test…
- Trial name
- NCT01921452
- Testing
- Quantitative POC TSH Kit, Qualitative POC TSH Kit, Third generation TSH Kit
- Where
- China
- Volunteers
- 283 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Healthy
BE of Euthyrox® Tablets (Merck Nantong Versus Merck Darmstadt Sites)
The purpose of this study is to demonstrate bioequivalence (BE) between Euthyrox® tablets manufactured at Merck Nantong (Test Euthyrox) versus the tablets manufactured at Merck Darmstadt (Reference Euthyrox).
- Trial name
- NCT05174000
- Testing
- Test Euthyrox®, Reference Euthyrox®
- Where
- China
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
Nonalcoholic Steatohepatitis (NASH)
Study to Evaluate the Safety, Tolerability, and Efficacy of ASC41 in Adults With NASH
This is a phase 2, randomized, double-blind, placebo controlled study in adults with biopsy confirmed NASH. The study is aimed at evaluating efficacy and tolerability of ASC41 in adults with NASH.
- Trial name
- NCT05118360
- Testing
- ASC41 2 mg, ASC41 4 mg
- Sponsor
- Gannex Pharma Co., Ltd.
Subclinical Hypothyroidism
Dietary Intervention With Únicla Dairy Products (DANTIAN)
Dietary intervention with Únicla dairy products, naturally enriched with selenium and omega-3 fatty acids, may improve thyroid-stimulating hormone (TSH) levels in women with subclinical hypothyroidism
- Trial name
- DANTIAN (NCT05019118)
- Testing
- Experimental milk, Experimental yogur, Experimental fresh cheese
- Where
- Spain
- Volunteers
- 90 people
- Sponsor
- Cooperativas Lacteas Unidas
Graves' Disease
A Study to Assess the Efficacy, Safety, and Tolerability of IMVT-1402 as Treatment for Adult Participants With Graves' Disease
This is a multi-center, global, randomized, double-blind, placebo-controlled Phase 2b study to assess the efficacy, safety, and tolerability of IMVT-1402 in adult participants with Graves' disease (GD) who are hyperthyroid…
- Trial name
- NCT07018323
- Testing
- IMVT-1402
- Where
- 163 sites in United States, Australia and 16 more
- Volunteers
- 210 people
- Sponsor
- Immunovant Sciences GmbH
Healthy
Study Comparing Thyrogen Versus a Modified Release of Recombinant Human Thyroid Stimulating Hormone
Forty-six (46) eligible, healthy subjects who provide written informed consent will be enrolled to participate in a 2 arm parallel group study to assess and compare the pharmacokinetics and safety profile of Thyrogen dosed at 0.1…
- Trial name
- NCT00137891
- Testing
- Modified Release rhTSH
- Where
- United States
- Volunteers
- 46 people, healthy volunteers welcome
- Sponsor
- Genzyme, a Sanofi Company
Non-Alcoholic Fatty Liver Disease
A Phase 3 Study to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Non Alcoholic Fatty Liver Disease Patients
A double-blind placebo controlled randomized Phase 3 study to evaluate the safety and tolerability of once-daily, oral administration of 80 or 100 mg resmetirom versus matching placebo.
- Trial name
- MAESTRO-NAFLD1 (NCT04197479)
- Testing
- Resmetirom
- Where
- 77 sites in United States, Puerto Rico
- Volunteers
- 1,343 people
- Sponsor
- Madrigal Pharmaceuticals, Inc.
Hypothyroidism
A Study Evaluating the Safety and Efficacy of Hormone Replacement Therapy With ST-1891 Compared to Levothyroxine in Patients With Primary Hypothyroidism
ST-1891-201 is a multicenter, randomized, double-blind, partial crossover, Phase 2 study evaluating the safety and efficacy of hormone replacement therapy with ST-1891 compared to levothyroxine in patients with primary…
- Trial name
- NCT05412979
- Testing
- ST-1891, Levothyroxine
- Where
- 39 sites in United States
- Volunteers
- 490 people
- Sponsor
- Sention Therapeutics, LLC
Hypothyroidism
A Study Evaluation the Safety and Efficacy of Hormone Replacement Therapy With North Star Compared to Levothyroxine in Patients With Primary Hypothyroidism
The North Star study is a multi-center, Phase 2, double-blind, randomized, parallel group clinical study to evaluate the safe and effective dose conversion from Levothyroxine to North Star therapy.
- Trial name
- NCT05712421
- Testing
- North Star, Levothyroxine
- Where
- 31 sites in United States
- Volunteers
- 303 people
- Sponsor
- Neuvosyn Laboratories, LLC
NSCLC (Non-small Cell Lung Cancer), Thyroid Cancer
Pralsetinib DDI Study in Patients With Advanced or Metastatic Solid Tumors
An open-label drug-drug interaction study to evaluate the effects of pralsetinib (Gavreto) on the pharmacokinetics of a CYP450 probe substrate cocktail and, in female participants, a hormonal probe substrate, in participants with…
- Conditions
- NSCLC (Non-small Cell Lung Cancer), Thyroid Cancer, Solid Tumor Malignancies, Advanced Malignancies
- Trial name
- NCT07704658
- Testing
- Pralsetinib, CYP3A4, CYP2C8, and CYP2C9 substrates, and hormonal contraceptive
- Where
- 2 sites in Spain
- Volunteers
- 12 people
- Sponsor
- Rigel Pharmaceuticals
Hormone Imbalance, Thyroid Hormone Imbalance
A Clinical Trial to Evaluate the Effects of a Supplement on Symptoms Associated With Hormone Imbalance
This study evaluates the effects of the Love Wellness Hello Burn, Balance supplement on symptoms associated with hormone imbalance, as measured by energy levels and healthy eating choices and habits.
- Conditions
- Hormone Imbalance, Thyroid Hormone Imbalance, Low Energy, Metabolic Symptoms
- Trial name
- NCT07765381
- Testing
- Hello Burn, Balance Supplement
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Love Wellness
Hypothyroidism, Thyroid Disease
A Study of Armour® Thyroid Compared to Synthetic T4 (Levothyroxine) in Previously Hypothyroid Participants
This study will evaluate the safe and effective dose conversion from levothyroxine (synthetic T4) therapy to Armour Thyroid therapy in participants who are on a stable dose of levothyroxine and have thyroid stimulating hormone…
- Conditions
- Hypothyroidism, Thyroid Disease, Euthyroid, Thyroid Gland
- Trial name
- NCT04124705
- Testing
- Armour® Thyroid, Levothyroxine
- Where
- 28 sites in United States
- Volunteers
- 284 people
- Sponsor
- Allergan
Metabolic Dysfunction-associated Steatohepatitis
A Study of a Thyroid Hormone Receptor Beta Isoform (THRβ) Agonist and an Semicarbazide Sensitive Amine Oxidase (SSAO) Inhibitor, Alone and in Combination, in Adults With Presumed Metabolic Dysfunction-associated Steatohepatitis (MASH)
The primary objective of this trial is to evaluate the dose-dependent and comparative effects of ECC4703 (low and high dose), ECC0509 (low and high dose), and their combination on hepatic fat reduction as assessed by change in…
- Trial name
- NCT07288138
- Testing
- ECC4703, ECC0509
- Where
- 68 sites in United States
- Volunteers
- 160 people
- Sponsor
- Eccogene
Graves' Disease
A Long-Term Extension Study of IMVT-1402 in Adult Participants With Graves' Disease (GD)
This is a long-term extension study that will rollover participants completing feeder studies IMVT-1402-2502 (NCT06727604) or IMVT-1402-2503 (NCT07018323) to evaluate the efficacy and safety of IMVT-1402 in adult participants…
- Trial name
- NCT07286006
- Testing
- IMVT-1402
- Where
- 131 sites in United States, Australia and 9 more
- Volunteers
- 372 people
- Sponsor
- Immunovant Sciences GmbH
Graves' Disease
Thyroid-Stimulating Hormone Receptor (TSHR) Blockade With REGN24493 in Adult Participants With Graves' Disease (GD)
This study will test an experimental Regeneron drug called REGN24493 hereby referred to as "study drug" to see if it can help treat Graves' disease.
- Trial name
- EMERGE (NCT07861152)
- Testing
- REGN24493
- Volunteers
- 45 people
- Sponsor
- Regeneron Pharmaceuticals
Menopause
A Comparison of Patch vs. Pill Estrogen Therapy on Testosterone Levels and Thyroid Tests in Menopausal Women
This study compares the effects of 12 weeks of treatment with transdermal versus oral estrogen therapy on testsoterone levels and thyroid tests in healthy, naturally menopausal women.
- Trial name
- NCT00224094
- Testing
- Premarin® (oral) vs. Alora® (transdermal)
- Where
- United States
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- Watson Pharmaceuticals
Non-Alcoholic Fatty Liver Disease
A Phase 3 Study to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Patients With Non-alcoholic Fatty Liver Disease (NAFLD), MAESTRO-NAFLD-Open-Label-Extension (MAESTRO-NAFLD-OLE)
A 52-Week, Multi-center, Open-label, Active Treatment Extension Study to Evaluate Safety and Tolerability of Once Daily, Oral Administration of Resmetirom (MGL-3196)
- Trial name
- NCT04951219
- Testing
- Resmetirom
- Where
- 76 sites in United States, Puerto Rico
- Volunteers
- 810 people
- Sponsor
- Madrigal Pharmaceuticals, Inc.
Healthy Volunteer
Safety, Tolerability, and Pharmacokinetics of ASC43F, a Fixed Dose Combination Tablet in Healthy Subjects
This is a phase 1, open-label study in healthy adults. This study is aimed at evaluating the safety, tolerability, and pharmacokinetics of ASC43F, a fixed-dose combination (FDC) and single dose tablet containing ASC41, a THR β…
- Trial name
- NCT05118516
- Testing
- ASC43F
- Where
- United States
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- Gannex Pharma Co., Ltd.